SP Tulsian of sptulsian.com told CNBC-TV18, "In Sun Pharma the USFDA issue for the time being has given some relief but there has been again a talk in the market that the company is also looking to acquire one company maybe about Rs 10,000 crore. In fact, I won't be talking too much of those details and all that, that is a premature or just a market gossip but that can be seen as a pricey acquisition if you take a call on that.""I don’t know which combination can revolve around USFDA. If we are just revolving around USFDA then probably the near-term relief has come but if you ask me, I won't be taking the stock as too comforting because this has seen as expensive and if you keep on maybe relying on the news of acquisitions or maybe USFDA comfort that can be short-lived. So take the stock more as a trading bet maybe in the range of Rs 750-830 or that kind of thing but I won't be taking a comforting investment call on the stock to have in the portfolio with six-eight months view," he added.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
